secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017857
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q1 net loss $94.2M; cash $937.8M; RLY-2608 shows no Grade 3 hyperglycemia
--------------------------------------------------------------------------------

- Net loss of $94.2M ($0.78 per share) vs $62.0M ($0.57) in Q1 2022; R&D expense $82.8M up from $51.7M.
- Cash, equivalents and investments $937.8M vs ~$1B at Dec 31 2022; expected to fund operations into 2025.
- Initial RLY-2608 data at AACR: no Grade 3 hyperglycemia/rash/diarrhea at target exposures; one confirmed partial response in breast cancer patient after cut-off.
- RLY-5836 first-in-human trial initiated in April 2023 for PIK3CA-mutant solid tumors; RLY-2139 candidate selected, clinical start early 2024.
- Full RLY-4008 dose escalation data accepted at ASCO 2023; expansion cohorts for RLY-2608 planned H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023017857/0000950170-23-017857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023017857/rlay-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer